List of Excipients in Branded Drug AMMONIUM LACTATE

Generic Drugs Containing AMMONIUM LACTATE

Company	Ingredient	NDC	Excipient
Padagis Israel Pharmaceuticals Ltd	ammonium lactate	45802-419	CETYL ALCOHOL
Padagis Israel Pharmaceuticals Ltd	ammonium lactate	45802-419	GLYCERIN
Padagis Israel Pharmaceuticals Ltd	ammonium lactate	45802-419	GLYCERYL MONOSTEARATE
Padagis Israel Pharmaceuticals Ltd	ammonium lactate	45802-419	LAURETH-4
Padagis Israel Pharmaceuticals Ltd	ammonium lactate	45802-419	LIGHT MINERAL OIL
Padagis Israel Pharmaceuticals Ltd	ammonium lactate	45802-419	MAGNESIUM ALUMINUM SILICATE

What are the Most Frequently-Used Excipients in AMMONIUM LACTATE?

# Of NDCs	Excipient
13	CETYL ALCOHOL
13	GLYCERIN
13	GLYCERYL MONOSTEARATE
13	LAURETH-4
13	LIGHT MINERAL OIL
13	MAGNESIUM ALUMINUM SILICATE

Ammonium Lactate Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 24, 2026

Ammonium lactate is a mature topical active used primarily at 12% concentration for xerosis, ichthyosis, keratosis pilaris, and other hyperkeratotic skin conditions. Its commercial value is concentrated in formulation performance, tolerability, packaging, consumer positioning, and distribution rather than active-ingredient exclusivity. The strongest opportunities are differentiated lotions, creams, sprays, body-care products, and private-label OTC products that improve sensory properties while maintaining ammonium lactate delivery and stability.

What is ammonium lactate used for?

Ammonium lactate is the ammonium salt of lactic acid. In topical products, it acts as a humectant and keratolytic agent. The most established pharmaceutical strength is ammonium lactate 12% lotion.

The FDA-approved prescription label for Lac-Hydrin 12% lotion identifies the product for treatment of xerosis and ichthyosis vulgaris. The label states that ammonium lactate increases skin hydration and may reduce scaling and roughness associated with abnormal keratinization.[1]

Common commercial uses include:

Use	Commercial relevance
Xerosis and dry skin	Core prescription and OTC indication
Ichthyosis vulgaris	Established dermatology use
Keratosis pilaris	Large consumer and dermatology opportunity, although product claims require regulatory control
Diabetes-associated dry skin	High-value pharmacy and podiatry channel
Eczema-associated xerosis	Adjunctive moisturization, subject to claim limitations
Foot, heel, and elbow care	Strong OTC and mass-market opportunity
Body moisturization	Consumer use of 12% and lower-strength products
Hyperkeratotic skin conditions	Specialty dermatology and compounding channels

Ammonium lactate is usually positioned against urea, lactic acid, salicylic acid, ceramides, petrolatum, and alpha-hydroxy-acid moisturizers. Its main differentiation is the combination of humectancy and mild exfoliation in a single topical active.

What FDA products contain ammonium lactate?

The principal pharmaceutical dosage form is a topical lotion containing 12% ammonium lactate. Generic products are marketed under labels such as ammonium lactate lotion, 12%.

FDA regulatory status

Ammonium lactate 12% lotion has an established prescription-drug history. Lac-Hydrin was approved as a prescription product, and multiple generic versions have been marketed through the abbreviated new drug application pathway.[1][2]

The regulatory landscape has two distinct segments:

1. Prescription ammonium lactate 12% lotion.
2. OTC and cosmetic products using ammonium lactate or lactic-acid-derived moisturizing claims.

Prescription products require an approved NDA or ANDA and must comply with prescription labeling. OTC products must fit an applicable FDA monograph or be marketed with cosmetic claims that do not cross into drug claims.

A product marketed for treating ichthyosis, xerosis as a disease, or other dermatologic conditions generally presents a drug-claim issue. A product marketed only to moisturize, soften, or smooth skin may qualify for cosmetic positioning, depending on its complete claims, labeling, website language, and advertising.

What excipients are used in ammonium lactate lotion?

Ammonium lactate lotion requires an excipient system that controls pH, odor, viscosity, skin feel, emulsion stability, and preservative performance. The reference product label identifies a conventional emulsion vehicle containing water, fatty alcohols, emollients, surfactants, and humectant components.[1]

A typical formulation architecture is:

Formulation function	Candidate excipient classes	Commercial purpose
Vehicle	Purified water	Primary continuous phase
Emolliency	Mineral oil, esters, dimethicone	Reduces dryness and tack
Structure	Cetyl alcohol, stearyl alcohol, glyceryl stearate	Builds viscosity and emulsion body
Humectancy	Glycerin, propylene glycol, glycols	Improves water retention
Emulsification	Nonionic surfactants, polysorbates, PEG esters	Stabilizes oil-in-water systems
Preservation	Parabens, phenoxyethanol, organic acids, approved preservative blends	Controls microbial growth
Chelation	Disodium EDTA or comparable chelator	Supports preservative performance and metal control
pH adjustment	Sodium hydroxide, citric acid, lactic acid, buffers	Controls skin compatibility and stability
Sensory modification	Silicones, light esters, volatile emollients	Reduces greasy or sticky feel
Packaging compatibility	Low-extractable tubes, pumps, airless systems	Controls contamination and dose delivery

The excipient strategy should start with ammonium lactate concentration and pH. Ammonium lactate can affect the product's odor, ionic strength, preservative system, and emulsion behavior. The final formulation must be evaluated for pH drift, viscosity change, phase separation, microbial robustness, package interaction, and active-content uniformity.

How should manufacturers optimize ammonium lactate excipients?

The primary formulation challenge is balancing efficacy with sensory acceptability. Higher ammonium lactate concentrations may improve keratolytic and moisturizing performance but can increase stinging, odor, and consumer abandonment.

Low-irritancy formulation

A low-irritancy product should use:

• A balanced emollient phase.
• Moderate rather than aggressive exfoliation.
• Controlled pH.
• Fragrance-free positioning for sensitive-skin users.
• Occlusive support from dimethicone, mineral oil, or suitable esters.
• A low-residue emulsion structure.

The label for Lac-Hydrin warns that stinging or burning can occur, particularly on fissured or inflamed skin, and recommends caution with sun exposure.[1] Product developers should therefore test the formulation on compromised skin models and avoid unnecessary irritants such as high fragrance loads, volatile alcohols, or poorly controlled pH.

Sensory optimization

Ammonium lactate products can be perceived as sticky, acidic, or medicinal. Commercially useful improvements include:

• Replacing heavy mineral-oil systems with lighter esters or silicone blends.
• Reducing tack through optimized humectant ratios.
• Using lamellar emulsions to improve barrier feel.
• Developing fast-absorbing lotions for daytime use.
• Using richer creams for overnight or severe-dryness positioning.
• Applying odor-control strategies without masking agents that increase sensitization risk.

Preservative strategy

The water-rich emulsion requires validated antimicrobial protection. Ammonium lactate, pH, surfactants, and packaging can each influence preservative efficacy. Preservative selection should be confirmed through antimicrobial effectiveness testing under the relevant United States Pharmacopeia standard and with the final commercial package.[3]

Preservative-free development is commercially attractive but technically difficult in a multidose lotion. It is more feasible with airless pumps, unit-dose packs, or anhydrous systems. Those formats increase packaging cost and may not be necessary for a low-price generic lotion.

What formulations are commercially attractive?

The largest formulation opportunities are not new chemical entities. They are differentiated delivery formats and improved consumer experiences.

Product concept	Target segment	Commercial rationale
Fragrance-free 12% lotion	Dermatology, sensitive skin	Supports professional recommendation and repeat use
Rich 12% cream	Severe xerosis, feet, elbows	Higher emolliency and overnight use
Fast-absorbing body lotion	Mass OTC	Improves adherence and cosmetic acceptability
Pump-packaged lotion	Family and daily use	Better dosing and lower contamination risk
Airless pump	Premium sensitive-skin segment	Supports preservative-reduction strategy
Travel or unit-dose format	Institutional, dermatology, travel retail	Convenience and hygiene
Foot-care cream	Podiatry and pharmacy	Targets high-need hyperkeratotic skin
Combination moisturizer	Consumer skin-care channel	Adds ceramides, dimethicone, or niacinamide
Lower-strength daily moisturizer	Cosmetic and OTC	Reduces irritation and expands frequency of use
Sprayable formulation	Large body areas	Differentiates application and accessibility

Combination products require careful claim and regulatory analysis. Adding ceramides or niacinamide can improve barrier positioning, but the additional ingredients do not automatically create a new drug indication or patentable product. A combination with a separately regulated active may trigger additional FDA requirements.

How many patents protect ammonium lactate products?

Ammonium lactate has limited current composition-of-matter protection. The active ingredient is old, and the principal 12% lotion concept has been commercially established for decades. Commercial entry is therefore unlikely to be blocked by a basic ammonium lactate patent.

The relevant intellectual-property categories are:

1. Formulation patents covering specific excipient ratios or emulsion structures.
2. Packaging patents covering pumps, dispensers, or contamination-control systems.
3. Manufacturing patents covering mixing, pH adjustment, particle control, or filling.
4. Method-of-use patents covering narrowly defined patient populations or treatment schedules.
5. Trademark rights covering brand names and trade dress.
6. Trade secrets covering fragrance systems, sensory modifiers, scale-up parameters, and preservative optimization.

A patent review should search the USPTO and international databases by ammonium lactate, ammonium 2-hydroxypropanoate, lactic acid ammonium salt, and relevant assignees.[4] The absence of an active-ingredient patent does not eliminate risk. A branded product can still assert later-filed formulation, packaging, or method patents if those claims are valid and applicable to the proposed product.

What is the Orange Book status of ammonium lactate?

The FDA Orange Book identifies approved drug products, patent information submitted by sponsors, and exclusivity information where applicable.[2] Ammonium lactate 12% lotion has a generic-drug history, which indicates that ANDA-based competition is commercially established.

The principal Orange Book questions for a proposed generic are:

• Whether the reference product remains listed as the relevant reference standard.
• Whether any patents are currently listed against the reference product.
• Whether listed patents require Paragraph IV certification.
• Whether any 30-month litigation stay has been triggered.
• Whether the proposed product is therapeutically equivalent to the reference product.
• Whether the applicant can qualify for a suitability petition or must file an ANDA with a full set of required comparative data.

For a mature topical product, regulatory risk may center more on pharmaceutical equivalence, product performance, microbiological quality, and comparative characterization than on patent exclusivity.

When does ammonium lactate lose exclusivity?

The principal exclusivity loss occurred years ago through generic entry. There is no meaningful remaining exclusivity period for the basic ammonium lactate 12% lotion concept.

A new product could obtain limited exclusivity only through a new FDA-approved product or a qualifying innovation, such as:

• A new dosage form.
• A new route of administration.
• A new indication supported by clinical data.
• A qualified pediatric indication.
• A novel drug-device combination.
• A new active or inactive ingredient presentation meeting applicable statutory requirements.

An improved lotion vehicle alone may support a patent application, but it does not automatically generate FDA exclusivity.

Are Paragraph IV challenges relevant to ammonium lactate?

Paragraph IV litigation risk is generally low for a mature ammonium lactate lotion unless an innovator has listed a live formulation or method-of-use patent. A generic applicant must still evaluate all Orange Book-listed patents and certify appropriately under the Hatch-Waxman framework.[2][5]

Potential Paragraph IV scenarios include:

• A new branded lotion with a patent covering a specific emulsion system.
• A drug-device product with a protected pump or applicator.
• A narrow method patent covering treatment of a defined patient subgroup.
• A reformulated product with a patent on preservative reduction or delivery characteristics.

For a standard 12% lotion using conventional excipients, the greater risks are product development and market economics rather than patent litigation.

Which companies compete in ammonium lactate?

Competition exists among branded prescription products, authorized or independent generics, OTC brands, private-label retailers, and adjacent moisturizer products.

Competitive categories

Competitor type	Competitive advantage
Prescription generic manufacturers	Low acquisition cost and pharmacy substitution
Established OTC brands	Consumer recognition and retail placement
Dermatology brands	Professional credibility and premium pricing
Private-label retailers	Low price and retailer control
Urea products	Strong competition in severe dryness and hyperkeratosis
Ceramide products	Barrier-repair positioning and broad consumer awareness
Salicylic-acid products	Strong keratolytic positioning
Petrolatum products	Low cost and high occlusivity

Ammonium lactate products compete on adherence. A product that feels better and is easier to apply can outperform a technically similar low-cost product in OTC channels, even when the active ingredient and concentration are identical.

What commercial opportunities exist for ammonium lactate?

The most attractive opportunities are in segments where consumers value repeated use and tolerability.

Dermatology and pharmacy

A fragrance-free 12% lotion with clear labeling, a pump dispenser, and low residue can support dermatologist and pharmacist recommendation. Professional channels favor consistent quality, reliable availability, and a familiar active ingredient.

Podiatry and diabetic foot care

Dry, cracked feet and hyperkeratotic areas are commercially important. Products marketed for diabetic consumers require careful claim control and should not imply treatment of diabetic complications without appropriate evidence and regulatory support.

Private-label retail

Private-label ammonium lactate lotion can compete effectively when the formulation meets a recognized reference standard and the retailer controls shelf placement. The economic model depends on low packaging cost, high manufacturing throughput, and limited SKU complexity.

Premium sensitive-skin products

A fragrance-free, dye-free, low-irritancy formulation with ceramides, dimethicone, or barrier-supportive excipients can command a higher retail price. The product should avoid unsupported claims such as eczema treatment unless the regulatory pathway supports those claims.

Institutional and long-term-care channels

Hospitals, nursing facilities, and home-health providers need economical moisturizers that are easy to dispense and have reliable microbiological quality. Pump formats can reduce contamination and improve staff workflow but increase unit cost.

What manufacturing and IP barriers affect market entry?

Manufacturing barriers are moderate. The product does not require a complex active-substance synthesis, but scale-up can create problems with:

• Emulsion viscosity.
• pH uniformity.
• Odor control.
• Preservative distribution.
• Active-content uniformity.
• Air incorporation during mixing.
• Tube or pump filling.
• Long-term phase stability.
• Microbial contamination during filling and use.

A manufacturing process should control the order of addition, temperature profile, shear rate, neutralization conditions, mixing endpoint, deaeration, and filling temperature. These parameters can become trade secrets even when they are not patent-protected.

Packaging is a meaningful barrier. Ammonium lactate lotion should be evaluated in tubes, bottles, pumps, and airless systems for leakage, sorption, extractables, leachables, actuator compatibility, and dose consistency. A superior package can support premium positioning, but it may reduce gross margin if the product is sold through discount pharmacy channels.

How strong is the ammonium lactate patent estate?

The basic patent estate is weak as a barrier to generic entry because the active ingredient and established lotion format are mature. A new entrant's defensibility depends on execution-specific rights.

Asset	Estimated strategic strength
Ammonium lactate active ingredient	Low
Standard 12% lotion	Low
Conventional excipient combination	Low to moderate
Novel emulsion or delivery system	Moderate
Proprietary pump or applicator	Moderate
New clinical indication	Moderate to high if supported
Brand and trade dress	Moderate in OTC markets
Manufacturing know-how	Moderate as a trade secret
Distribution and professional recommendation	High commercial value, limited patent value

Patent strength should be assessed claim by claim. Narrow excipient patents may be difficult to enforce if competitors can design around concentration ranges, emulsifier classes, or process limitations.

What is the outlook for generic launch scenarios?

A standard ammonium lactate 12% lotion can enter through a conventional generic strategy if the reference product, dosage form, strength, route, and labeling requirements are satisfied. Launch economics are likely to be most attractive in the following situations:

1. A retailer seeks a private-label supply arrangement.
2. A manufacturer can produce multiple topical emulsions on the same line.
3. The product has a differentiated pump or cream vehicle.
4. A supplier can secure dermatology or podiatry distribution.
5. The company avoids excessive SKU fragmentation.

A low-price generic launch faces limited differentiation and pharmacy-level price competition. A branded OTC launch requires investment in consumer education, retail placement, packaging, and repeat-use performance.

Key Takeaways

• Ammonium lactate 12% lotion is a mature topical pharmaceutical product with limited basic patent protection.
• The principal commercial opportunity is formulation and channel differentiation, not active-ingredient exclusivity.
• Excipient selection should prioritize low tack, low odor, controlled pH, emulsion stability, preservative robustness, and skin tolerability.
• Fragrance-free lotions, rich creams, pump systems, foot-care products, and private-label formats offer the clearest opportunities.
• Generic entry and Paragraph IV risk are generally lower than for recently approved topical drugs, but current Orange Book listings must be checked before filing.
• Manufacturing process control and packaging compatibility can create meaningful trade-secret and commercial advantages.
• Revenue potential is difficult to isolate because ammonium lactate sales are distributed across prescription generics, OTC brands, private-label products, and adjacent moisturizers.

FAQs

Is ammonium lactate the same as lactic acid?

No. Ammonium lactate is the ammonium salt of lactic acid. Both are used in topical skin-care products, but their formulation behavior, pH, odor, and labeling differ.

Can ammonium lactate lotion be sold over the counter?

Some products may be marketed OTC or as cosmetics, depending on formulation, claims, labeling, and applicable FDA requirements. Claims to treat a disease or dermatologic condition can cause the product to be regulated as a drug.

What is the most commercially useful strength of ammonium lactate?

The established pharmaceutical strength is 12%. Lower-strength products may offer better tolerability and cosmetic appeal, while higher-strength or specialized formulations may face greater irritation and regulatory scrutiny.

Are ceramides compatible with ammonium lactate?

Ceramides can be incorporated into ammonium lactate emulsions, but the formulation must control dispersion, emulsion stability, pH, preservative efficacy, and sensory performance.

Does ammonium lactate have biosimilar competition?

No. Ammonium lactate is a small-molecule topical active, not a biologic. Competition occurs through generic-drug, OTC, cosmetic, and private-label pathways rather than biosimilar approval.

References

1. U.S. Food and Drug Administration. (n.d.). Lac-Hydrin 12% lotion prescribing information. Drugs@FDA and product labeling database.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. United States Pharmacopeia. (2024). General chapter <51>: Antimicrobial effectiveness testing. United States Pharmacopeial Convention.

4. United States Patent and Trademark Office. (n.d.). Patent Center and Patent Public Search. U.S. Department of Commerce.

5. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Content and format. FDA guidance and regulatory resources.